Literature DB >> 18297719

Possible molecular mechanism of the relationship between NS5B polymorphisms and early clearance of hepatitis C virus during interferon plus ribavirin treatment.

Mitsuyasu Nakamura1, Hidetsugu Saito, Masanori Ikeda, Shinichiro Tada, Naoki Kumagai, Nobuyuki Kato, Kunitada Shimotohno, Toshifumi Hibi.   

Abstract

We previously reported the relationship between viral polymerase polymorphisms and the initial decline in viral load induced by interferon-alpha and ribavirin therapy in genotype 1b-related chronic hepatitis C patients. The presence of E124K and I85V of NS5B was closely associated with viral clearance at 8 weeks of treatment. The aim of this study was to investigate the mechanisms by which this polymorphism of NS5B protein affects early viral clearance. We used a replicon system derived from strain O, genotype 1b virus. Three mutants (V85I), (K124E), and (V85I/K124E) were introduced to the replicon. OR6c, a derivative of HuH7 cells, was transfected with the replicon including a luciferase reporter gene. Luciferase activities were measured 72 hr post-transfection. All three mutants showed higher luciferase activity than that of the wild type, and the V85I mutant showed the highest activity. This result was also confirmed by neomycin gene-containing replicons with same mutations. All replicons were down-regulated by ribavirin, but the level of reduction in the V85I mutant was the lowest. Our results suggested that this mutation at least partly contributes to resistance to early viral clearance during interferon and ribavirin combination therapy.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18297719     DOI: 10.1002/jmv.21125

Source DB:  PubMed          Journal:  J Med Virol        ISSN: 0146-6615            Impact factor:   2.327


  5 in total

Review 1.  The application and mechanism of action of ribavirin in therapy of hepatitis C.

Authors:  Emmanuel Thomas; Marc G Ghany; T Jake Liang
Journal:  Antivir Chem Chemother       Date:  2012-09-25

Review 2.  Polymerases of paramyxoviruses and pneumoviruses.

Authors:  Rachel Fearns; Richard K Plemper
Journal:  Virus Res       Date:  2017-01-16       Impact factor: 3.303

3.  An antioxidant resveratrol significantly enhanced replication of hepatitis C virus.

Authors:  Mitsuyasu Nakamura; Hidetsugu Saito; Masanori Ikeda; Ryota Hokari; Nobuyuki Kato; Toshifumi Hibi; Soichiro Miura
Journal:  World J Gastroenterol       Date:  2010-01-14       Impact factor: 5.742

4.  On-treatment predictions of success in peg-interferon/ribavirin treatment using a novel formula.

Authors:  Hidetsugu Saito; Hirotoshi Ebinuma; Keisuke Ojiro; Kanji Wakabayashi; Mika Inoue; Shinichiro Tada; Toshifumi Hibi
Journal:  World J Gastroenterol       Date:  2010-01-07       Impact factor: 5.742

5.  Prediction of effect of pegylated interferon alpha-2b plus ribavirin combination therapy in patients with chronic hepatitis C infection.

Authors:  Tetsuro Takayama; Hirotoshi Ebinuma; Shinichiro Tada; Yoshiyuki Yamagishi; Kanji Wakabayashi; Keisuke Ojiro; Takanori Kanai; Hidetsugu Saito; Toshifumi Hibi
Journal:  PLoS One       Date:  2011-12-02       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.